Legend Biotech Corp. ADR (LEGN): Price and Financial Metrics

Legend Biotech Corp. ADR (LEGN): $42.61

1.81 (+4.44%)

POWR Rating

Component Grades








Add LEGN to Watchlist
Sign Up

Industry: Biotech




#112 of 348

in industry

LEGN Price/Volume Stats

Current price $42.61 52-week high $77.32
Prev. close $40.80 52-week low $38.60
Day low $40.63 Volume 1,104,300
Day high $42.84 Avg. volume 1,075,527
50-day MA $44.78 Dividend yield N/A
200-day MA $57.72 Market Cap 7.77B

LEGN Stock Price Chart Interactive Chart >

Legend Biotech Corp. ADR (LEGN) Company Bio

Legend Biotech Corp. is a holding company which engages in the discovery and development of novel cell therapies for oncology and other indications. It carries out its operations through the North America, and China geographical segments. The company was founded in May 2015 and is headquartered in Somerset, NJ.

LEGN Latest News Stream

Event/Time News Detail
Loading, please wait...

LEGN Latest Social Stream

Loading social stream, please wait...

View Full LEGN Social Stream

Latest LEGN News From Around the Web

Below are the latest news stories about LEGEND BIOTECH CORP that investors may wish to consider to help them evaluate LEGN as an investment opportunity.

13 High Growth Healthcare Stocks to Buy

In this article, we will take a look at 13 high growth healthcare stocks to buy. To skip our analysis of the recent market activity, you can go directly to see the 5 Best High Growth Healthcare Stocks to Buy. For the purpose of this article, we have defined high growth stocks as stocks that […]

Yahoo | December 26, 2023

Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)

SOMERSET, N.J., December 12, 2023--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life-threatening diseases, announced today patient-reported outcome (PRO) data from the Phase 3 CARTITUDE-4 study from an oral presentation at the 2023 American Society of Hematology (ASH) Annual Meeting (Abstract #1063). These data showed clinically meaningful improvement in health-related quality of

Yahoo | December 12, 2023

CAR T-Cell Therapies Under FDA Watch on Reports of Malignancies

The FDA has undertaken an investigation of T-cell malignancies in patients undergoing CAR T-cell therapy treatment. Therapies from NVS, BMY and GILD are under the spotlight.

Yahoo | November 29, 2023

FDA Looking Into All Approved CAR T Therapies on Risk of Cancer in White Blood Cells

The U.S. Food and Drug Administration is investigating certain CAR T cancer therapies based on reports that they might cause a type of white blood cell to become cancerous in patients who received the treatment.

Yahoo | November 28, 2023

Legend Biotech Corporation (NASDAQ:LEGN) Q3 2023 Earnings Call Transcript

Legend Biotech Corporation (NASDAQ:LEGN) Q3 2023 Earnings Call Transcript November 20, 2023 Legend Biotech Corporation beats earnings expectations. Reported EPS is $-0.17, expectations were $-0.56. Operator: Good day, ladies and gentlemen. Thank you for standing by. Welcome to Legend Biotech Reports Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in […]

Yahoo | November 24, 2023

Read More 'LEGN' Stories Here

LEGN Price Returns

1-mo 0.02%
3-mo -26.71%
6-mo -28.77%
1-year -43.19%
3-year 7.30%
5-year N/A
YTD -29.18%
2023 20.53%
2022 7.10%
2021 65.52%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!